VTE risk varies by hormone therapy formulation

VTE risk varies by hormone therapy formulation
The risk of venous thromboembolism in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest risk seen in users of oral estrogen-progestin HT containing medroxyprogesterone acetate, according to research published online Sept. 10 in the Journal of Thrombosis and Haemostasis.

(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin HT containing medroxyprogesterone acetate, according to research published online Sept. 10 in the Journal of Thrombosis and Haemostasis.

Siân Sweetland, M.D., of the University of Oxford in the United Kingdom, and colleagues conducted a study using data from 1,058,259 to evaluate the association of VTE with HT use.

The researchers found that the risk of VTE in women using oral estrogen-progestin and oral estrogen-only HT was 2.07- and 1.42-fold higher, respectively, than for women who had never used HT. The risk of VTE was highest for formulations containing acetate. Similar results were observed for , with or without pulmonary embolism. The overall odds of experiencing a VTE event ranged from one in 250 for estrogen-progestin with medroxyprogesterone acetate, one in 390 for estrogen-progestin HT containing norethisterone/norgestrel, one in 475 for oral estrogen-only HT, to one in 660 postmenopausal women who had never used HT.

"Both route of administration and the specific constituents of HT have a significant impact on the risk of VTE in middle-aged women," the authors write. "The risk of VTE was highest for current users of oral combined estrogen-progestin HT at the time of last contact and in particular for users of estrogen-progestin preparations containing medroxyprogesterone . Risk was lower but significantly increased in users of oral estrogen-only HT, but there was no increased risk for current users of transdermal estrogen HT."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Menopausal hormone therapy and breast cancer risk

Mar 15, 2012

In the past decade, results from large prospective cohort studies and the Women's Health Initiative (WHI) randomized placebo-controlled hormone therapy trials have substantially changed thoughts about how estrogen alone and ...

The Women's Health Initiative: An unforgettable decade

May 31, 2012

The 10-year anniversary of the historic Women's Health Initiative (WHI) Hormone Therapy Trial report, which radically changed the practice of women's health, will be commemorated in July 2012. In anticipation of this event, ...

Recommended for you

Fatigue, fear are daily lot of Ebola fighters: experts

4 hours ago

Doctors, nurses and hospital workers fighting the Ebola epidemic in west Africa are struggling with a daily burden of exhaustion, shortage of staff and fear for themselves over the deadly virus, specialists say.

Hong Kong makes Ebola 'contingency' measures

7 hours ago

Hong Kong said Wednesday it was quarantining all people from Guinea, Sierra Leone and Liberia who were showing Ebola-like symptoms on arrival in the city, as fears grow worldwide about the spread of the deadly virus.

User comments